Rheumatoid arthritis treatment in new class of medicines

A new oral treatment alternative for patients with moderate to severe rheumatoid arthritis, will be available on the PBS from 1 October, 2015. Pfizer's Xeljanz (tofacitinib citrate) has been approved to treat adults with moderate to severe active rheumatoid arthritis, who have had an inadequate response to conventional disease-modifying antirheumatic drugs, such as methotrexate. Xeljanz